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The objective of this research was to design a new colon‑targeted drug delivery system based on chitosan. 
The properties of the films were studied to obtain useful information about the possible applications of 
composite films. The composite films were used in a bilayer system to investigate their feasibility as 
coating materials. Tensile strength, swelling degree, solubility, biodegradation degree, Fourier Transform 
Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), Scanning Electron Microscope 
(SEM) investigations showed that the composite film was formed when chitosan and gelatin were reacted 
jointly. The results showed that a 6:4 blend ratio was the optimal chitosan/gelatin blend ratio. In vitro drug 
release results indicated that the Eudragit‑ and chitosan/gelatin‑bilayer coating system prevented drug 
release in simulated intestinal fluid (SIF) and simulated gastric fluid (SGF). However, the drug release 
from a bilayer‑coated tablet in SCF increased over time, and the drug was almost completely released 
after 24h. Overall, colon-targeted drug delivery was achieved by using a chitosan/gelatin complex film 
and a multilayer coating system.
Uniterms: Chitosan/evaluation. Chistosan/evaluation/gelatin complex film. Drugs/administration. Drugs/
delivery system/Colon‑targeting. Tablets/bilayer‑coated. 
INTRODUCTION
Colon‑targeted drug delivery systems have been 
increasing interest for treating colonic diseases such as 
Crohn’s disease, irritable bowel syndrome, and ulcerative 
colitis (Chourasia, Jain, 2004; Jain, Jain, 2008; Luo et al., 
2011). Colon-targeted drug delivery increases efficacy and 
reduces side effects by delivering high drug concentrations 
topically at the colonic disease site. An ideal colon‑
specific drug delivery system should release most of the 
drug locally into the colon, and not into the stomach or 
small intestine (Rubinstein, 1995). Several strategies are 
currently being investigated for colon-specific delivery, 
including prodrugs (Dhaneshwar et al., 2007) and pH‑
sensitive (Yin et al., 2008; Vaghani, Pateland, Satish, 
2012), time‑dependent (Cui et al., 2007), and microflora-
activated systems (Dev, Bali, Pathak, 2011; Yang, 2008).
The pH of the gastrointestinal tract gradually 
increases as one moves down the gastrointestinal tract 
from the stomach (pH 1.5‑3) to the terminal ileum (pH 
7-8) (Gupta, Beckert, Price, 2001). pH‑sensitive delivery 
systems takes advantage of polymeric materials that 
are insoluble in the low pH environment of the upper 
gastrointestinal tract, but dissolve at the higher, near 
neutral pH of the distal gut. Microflora-activated delivery 
systems are preferable and promising (Fan et al., 2009). 
The human colon is a dynamic and ecologically diverse 
system consisting of over 400 distinct bacterial species 
(Cummings, Macfarlane, 1991) that secrete a variety 
of enzymes (Guarner, Malagelada, 2003). The primary 
sources of nutrition for these bacteria are non‑starch 
polysaccharides which are fermented during their transit 
through the colon and which are negligibly broken down 
in the stomach and small intestine (Englyst, Cummings, 
1985). Currently, natural polysaccharides are extensively 
used for the development of solid dosage forms for the 
delivery of drugs to the colon (Nath, Nath, 2013).
Y. Ren, L. Jiang, S. Yang, S. Gao, H. Yu, J. Hu, D. Hu, W. Mao, H. Peng, Y. Zhou
Braz. J. Pharm. Sci. 2017;53(1):e15009Page 2 / 11
However, it was reported that a colon‑specific 
delivery system which is based only on pH‑sensitive 
(Gupta, Beckert, Price, 2001) or microflora‑activated 
systems have been reported as unreliable due to the 
inherent variability in pH or water swelling from the 
gastrointestinal tract. Fortunately, a bilayer system would 
serve as a unique drug delivery device that is compatible 
with conventional manufacturing methods. Similarly, 
multi‑layered tablets have been developed to control drug 
delivery using a predefined release profile for different 
active ingredients. Therefore, we intend to design a new 
drug delivery system by a combining pH‑sensitive system 
with microflora-activated system. 
Polysaccharides, which are metabolized by 
the colonic flora, have gained widely attention as 
potential colon targeting carriers for their non‑toxic, 
hydrophilic, gel‑forming, biodegradable, inexpensive, 
and abundant properties and they are available in various 
grades of varying properties. Chitosan, which is a high 
molecular weight natural polysaccharide, is completely 
biodegradable, non‑toxic, low‑cost, and has favorable 
gelation characteristics (Singla, Chawla, 2001). Chitosan 
cannot be digested in the upper gastrointestinal tract by 
human digestive enzymes (Bhattarai, Gunn, Zhang, 2010; 
Park et al., 2010). However, chitosan is prone to glycosidic 
hydrolysis by microbial enzymes in the colon (Chourasia, 
Jain, 2003; McConnell, Murdan, Basit, 2008; Muzzarelli, 
2011). Furthermore, chitosan has been applied in colon‑
targeted drug delivery systems in several forms such as 
capsules (Tozaki et al., 2002), matrices (Zambito, Di 
Colo, 2003), hydrogels (Zhang, Alsarra, Neau, 2002) and 
microspheres (Lorenzo‑Lamosa et al., 1998). Therefore, 
the potential for chitosan to be used as a coating material 
is obvious. However, chitosan dissolves in the acidic 
solutions, i.e., a factor that would limit the applications 
of chitosan in colon-targeted drug delivery. Gelatin 
is a soluble protein compound obtained by partially 
hydrolyzing collagen. It has a number of applications in 
the biomedical field, such as in tissue engineering, wound 
dressing, drug delivery and gene therapy (Mano et al., 
2007). Furthermore, gelatin films, which are thin, flexible 
and transparent biodegradable materials, are available 
for engineering food, packaging, drug delivery and other 
applications (Bergo, Sobral, 2007). Unfortunately, gelatin 
exhibits poor mechanical properties, limiting its possible 
applications. Blending is an easy way to improve the 
properties of polymer materials. Based on the above, a 
chitosan/gelatin complex film was prepared as an inner 
coat. Eudragit® L100, anionic copolymers, dissociates 
above pH 6.0 and was used as the outer coat.
The objective of this study was to develop a multi‑
unit delivery system of a model drug so that the majority of 
the drug release occurs in the colon in a sustained‑release 
fashion. A schematic of the delivery system is shown 
in Figure 1. Hydrocortisone is more extensively used 
as a corticosteroid to cure inflammatory bowel disease. 
Hydrocortisone was used as a model drug in this study. 
Tablets were chosen for development because they are 
more economical and easier to industrialize.
MATERIAL AND METHODS
Material 
Hydrocortisone was purchased from Jinjin 
Pharmaceutical Co. Ltd. (Tianjin, China). The following 
excipients and chemicals were purchased from commercial 
sources and used as received: chitosan (deacetylation 
degree 96%, Haidebei Co. Ltd., Shandong, China), 
microcrystalline cellulose (MCC, Huzhou Zhanwang 
Medical Company, Huzhou, China), Eudragit® L100 
(Röhm Pharm, Darmstadt, Germany), triethylcitrate 
(TEC, Johnson Matthey company, USA), polyethylene 
glycol (PEG) 6000 (Pudong Chemical Co., Shanghai, 
China), talc and magnesium stearate (Shanghai Yunhong 
Pharmaceutical Excipients & Technology Co. Ltd., 
Shanghai, China), lactose and gelatin (Beijing Aoboxing 
Biotechnology, Beijing, China), and pepsin, lipase 
and pectinase (Beijing Kebio Biotechnology, Beijing, 
China). The solvents were reagent grade; double distilled 
deionized water was used in all experiments.
Film preparation
Gelatin was dissolved in ultra-pure water, and 
chitosan was dissolved in a 2% acetic acid solution. The 
gelatin and chitosan solutions were mixed at different 
weight ratios (Table I) and PEG6000 was added as a 
plasticizer. Subsequently, the mixed solution was stirred 
for 15 min at room temperature. In this reaction, the gelatin 
and the chitosan array formed a complex. Subsequently, 
the mixtures were cast onto silanized glass Petri dishes and 
dried at room temperature for 5‑7 days. After drying, the 
FIGURE 1 - Bilayer coated tablet. Bilayer coated tablet was 
prepared in this study (A); shematic of the bilayer coated tablet 
delivery system (not to scale) (B).
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gelatin/chitosan films were removed from the Petri dishes 
and stored in desiccators at room temperature.
Preparation of the simulated gastric/intestinal 
fluid
Preparation of the simulated gastric/intestinal fluid with 
enzyme
According to the prepared method of the simulated 
gastric/intestinal fluid in the Chinese Pharmacopoeia 
2010, a simulated gastric fluid (SGF) was prepared 
comprising an aqueous solution containing 12,000 U/L 
pepsin adjusted to pH 1.5 using 0.1 M HCl. A simulated 
intestinal fluid (SIF) was prepared comprising an 8400 
U/L lipase solution in a phosphate buffer (pH 7.4). A 
simulated colonic fluid (SCF) was prepared comprising 
a 6 g/L pectinase solution in a phosphate buffer (pH 6.8).
Preparation of the simulated colonic fluid with rat 
colonic medium (RCM)
The extracellular enzymes released from the 
microflora in rat colonic contents had more profound 
degradation effects on chitosan than their membrane 
enzymes (Zhang, Alsarra, Neau, 2002). Therefore, rat 
colonic medium was prepared. Male Wistar rats (200‑300 
g) were lightly anesthetized using ether, and sacrificed by 
decapitation. Their caeca were exteriorized, cauterized 
at both ends (2.0 cm apart), cut loose, and immediately 
removed from the rat body. The formed cecal bag was 
opened, and its contents were weighed, pooled, and 
suspended in two volumes of cold bicarbonate-buffered 
saline to give a final cecal dilution of 33% (w/v). The 
suspension was filtered through a 400 mesh grit twice to 
remove any debris. The supernatant was then centrifuged at 
15,000 x g for 30 min to obtain a clear supernatant containing 
the extracellular enzymes (Zhang, Alsarra, Neau, 2002). 
The animal study protocol was approved by the Animal 
Care and Use Committee of Harbin Medical University.
Film characteristics
Appearance
The surface conditions and color of the gelatin/
chitosan films were observed.
Thickness
The thickness of the gelatin/chitosan films was 
determined with a micrometer, and the average value of 
10 measurements taken at random points was reported.
Tensile strength measurement
The gelatin/chitosan films were cut into rectangular 
samples. Four tests were performed with each film at room 
temperature using an electronic universal testing machine 
BLD 200S (Jinan, China). The characteristic parameters 
of the rectangular samples included a 40‑mm gauge length 
and a 10‑mm width. Average values from at least three 
measurements were reported. The tensile strength (TS) 
was calculated using the following expression:
 δ=P/(b•d) (1)
where δ is the tensile strength, P is the maximal tension 
needed to break the film, b is the width of the film and d 
is the thickness of the film.
Swelling of film
The  deg ree  o f  swe l l i ng  was  de t e rmined 
gravimetrically. Films 20 mm long and 20 mm wide were 
put into SGF, SIF and SCF without enzymes to swell at the 
experimental temperature. The samples were removed at 
regular intervals from the buffers, blotted with filter paper, 
weighed and replaced in the same immersion bath. This 
process was repeated until a swelling equilibrium was 
reached. The swelling degree was defined as the weight of 
water imbibed by the sample per unit weight of film. Each 
film was analyzed three times. The equilibrium swelling 
degree Q∞ was calculated in grams of water per gram of 
film using the following expression:
 Q∞ (%) = (m∞−m0) x 100/m0 (2)
where m0 is the initial weight of the dried film, and m∞ is 
the weight of film at swelling equilibrium.
TABLE I - Formulation design of film
Formulation 
No. (FN) Composition Weight Rate
1 Gelatin/chitosan/PEG 10:0: 1
2 Gelatin/chitosan/PEG 9:1:1
3 Gelatin/chitosan/PEG 8:2:1
4 Gelatin/chitosan/PEG 7:3:1
5 Gelatin/chitosan/PEG 6:4:1
6 Gelatin/chitosan/PEG 5:5:1
7 Gelatin/chitosan/PEG 4:6:1
8 Gelatin/chitosan/PEG 3:7:1
9 Gelatin/chitosan/PEG 2:8:1
10 Gelatin/chitosan/PEG 1:9:1
11 Gelatin/chitosan/PEG 0:10:1
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Solubility of film
Dried films (n=3) were weighed (W1) and immersed 
in SGF, SIF and SCF without enzyme for 24 h, dried in 
vacuo overnight, and weighed again (W2). The solubility 
of each sample was determined three times. Solubility (S) 
was calculated using Eq. (3):
 S (%) = (W1‑W2) x 100/W1 (3)
Fourier transform infrared spectroscopy (FTIR)
The films were cut into small pieces and KBr discs 
were prepared. Infrared spectra were recorded on an 8400S 
FTIR spectrometer (Shimadzu, Japan) in the 4000‑400 
cm−1 region.
Differential Scanning Calorimetry (DSC)
DSC assays of gelatin/chitosan/PEG mixtures and 
gelatin/chitosan films were performed by using a DZ3335 
DSC (Nanjingdazhan, China) instrument. A sample (5mg) 
was scanned in an aluminum pan over a temperature range 
between 35°C to 340°C under nitrogen at a scanning rate 
of 5°C/min. All scans were performed in triplicate.
Scanning electron microscope (SEM) analysis
Surface morphologies were examined by SEM 
using a S3400N scanning microscope from Hitachi Ltd. 
Co. (Tokyo, Japan) at an accelerating voltage of 15 kV. 
Samples were mounted on metal stubs and coated with 
gold by ion sputtering instrument E‑1010.
Characterization of biodegradation 
The gelatin/chitosan films with thicknesses 
averaging 0.6‑0.8 mm were cut into 2 cm×2 cm pieces. 
The film samples were degraded in 20 ml SGF (2 h), SIF 
(24 h), SCF (24 h) or RCM (24 h). Each sample was tested 
three times. The degradation degree (Dt) at time t was 
calculated using the following expression: 
 Dt = (mt −m0)/m0  (4)
where m0 is the initial weight of the dried film (at t=0), and 
mt is the weight after a time t.
Preparation and evaluation of colon-targeted 
tablets
Core tablet preparation
The formulation of prototypical core tablets 
containing 10 mg hydrocortisone were prepared using 
a wet granulation technique. The tablets contained 
46% MCC, 46% lactose, 2% PVPP and 1% magnesium 
stearate. The drug and excipients were mixed. The dry 
blend was granulated with 3% aqueous PVPK30 solution 
as the binding solution, passed through a no. 16 mesh, 
and dried at 55 °C on a tray drier. The dried granules were 
passed through a no. 20 mesh before they were blended 
with 1.0% (w/w) magnesium stearate and compressed 
using an 8‑mm punch on a single punch tablet press 
(DP30A, Beijing Gylongli Sci. & Tech. Co., Ltd., China). 
Core tablets were evaluated based on friability, hardness 
and disintegration.
Preparation of coating tablets
Three layers of polymeric coatings were applied 
to all core tablets in the following order: HPMC, gelatin/
chitosan and Eudragit L100. The HPMC coat formulation 
was prepared by dissolving 2% (w/v) HPMC in 80% 
ethanol HPMC, the gelatin/chitosan coat formulation was 
gelatin (2%, w/v), chitosan (3%, w/v), PEG (0.5%, w/v), 
and 3% talc (3%, w/v) in 2% acetic acid solution, and the 
Eudragit L100 coat formulation was Eudragit L100 (6%, 
w/v), triethyl citrate (1%, w/v), and talc (3%, w/v) in an 
ethyl alcohol/water mixture(96/4). The coating weight 
gains for the HPMC, Eudragit L100 and gelatin/chitosan 
formulations were 2%, 4% and 20%, respectively.
In vitro dissolution testing
Hydrocortisone release profiles from uncoated, 
gelatin/chitosan‑coated, Eudragit‑coated and bilayer‑
coated tablets were assessed by three‑step dissolution 
experiments (Liu et al., 2007), which were carried out 
in RC‑6 dissolution tester (Tian Jin Optical Instrument 
Factory, China) to simulate the GIT under physiological 
conditions (250 ml per vessel): 2 h in SGF, 4 h in SIF 
and finally, 24 h in SCF. The stirring rates in SGF, SIF 
and SCF were 20, 20, and 5 rpm, respectively, and the 
temperature was maintained at 37 °C. Aliquots of the 
dissolution medium were withdrawn at predetermined 
times and replaced with the same volume of corresponding 
release medium to maintain a consistent volume. Each 
test was performed in triplicate and the release of 
hydrocortisone was monitored at 243 nm (UV 2000 UV‑
vis spectrophotometer).
Stability studies 
The bilayer‑coated tablets were stored in a high‑
density polyethylene plastic bottle with silica gel. A 
stability study of the bilayer‑coated tablet was carried out 
according to ICH guidelines at 40±2 °C/75%±5% RH 
(Nagendra, Roopa, Gurinder, 2014). Physical attributes of 
the tablets, i.e., appearance, percentage drug content and 
dissolution profiles were tested over a period of 6 months. 
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Data analysis
The Rank Sum Ratio (RSR) method was used to 
evaluate the effect of the formulation composition on films 
using seven indices: tensile strength (TS), swelling degrees 
(Q) in SIF and SCF without enzyme, solubility (S) in SIF 
and SCF without enzyme, and biodegradation degree (D) 
in SIF and in SCF. High TS, Q in SCF without enzyme 
(QC), S in SCF without enzyme (SC) and D in SCF (DC), 
and low Q in SIF (QI), S in SIF without enzyme (SI) and 
D in SIF (DI) facilitate better film performance. Therefore, 
TS, QC, SC and DC were the high optimization indices. 
QI, SI and DI were the low optimization indices. The best 
film was identified by Eq. (5): 
   (5)
where n represents the line, j represents the array and Rnj 
is the rank of n among the j indices.
SPSS11.5 software was used for all statistical 
analyses. A value of P<0.05 was considered significant.
RESULTS AND DISCUSSION
Film characteristics
Film appearance and thickness
The gelatin/chitosan films were homogeneous, 
transparent and slightly brittle. The color of the films 
deepened as the chitosan content increased.
The average thicknesses of the films are listed in 
Table II. The thickness of the films significantly increased 
from 0.058 to 0.079 mm when the chitosan content 
increased. The film thickness was likely to be dependent 
on the film nature and composition. This result was similar 
to the resulst reported by Sebti et al. (2007) and Di Pierro 
et al. (2006) who showed possible relationships between 
film thickness and film‑forming polymer content and 
nature. 
Tensile strength measurement
The tensile strengths (TS) of the gelatin/chitosan 
films are presented in Table II. The TS of the composite 
membrane increased compared with the chitosan film, and 
the mechanical behavior of the composite film improved 
due to the added gelatin. A few studies have suggested 
that films formed from mixtures likely improved their 
physicochemical properties (Di Pierro et al., 2006; 
Prodpran, Benjakul, Artharn, 2007). Chitosan contains 
more functional groups such as hydroxyls, amines 
and amides, whereas gelatin has more carboxyl and 
amino groups (Celasco et al., 2008). These groups may 
form electrostatic and hydrogen bonding interactions. 
Furthermore, when the gelatin and chitosan films were 
prepared, the non‑covalent interactions, such as hydrogen 
bonding and hydrophobic interactions, likely formed 
between the gelatin and chitosan molecules (Cao, Fu, He, 
2007). Therefore, the tensile strength of the composite 
film increased due to the non‑covalent interactions 
between gelatin and chitosan. However, when the chitosan 
content continued to increased up to and beyond a 60% 
mass fraction, the TS of the composite film decreased. 
There may not have been enough gelatin to form the non‑
covalent interactions with chitosan.
Influence of the simulated gastrointestinal tract 
environment on the complex film
The swelling behavior, solubility and the in vitro 
degradation of the films are reported in Table III. The 
Q∞ values revealed that all the films had water retention 
capabilities. The Q∞ values of the blended films depended 
on the chitosan/gelatin blend ratios and the physical 
structure of the films. The composite films had improved 
the mechanical strength, thermal stability, and swelling 
capability of films. The Q∞ slightly decreased with the 
chitosan content increasing in SIF and SCF; Q∞ was 
smaller when the chitosan content was 50%‑80%. These 
results agreed with studies that reported composite films 
improved mechanical strength (McConnell, Murdan, 
Basit, 2008) and swelling capability of films (Rueda, 
Secall, Bayer, 1999).
The  ab i l i t y  t o  r egu la t e  t he  so lub i l i t y  o f 
biodegradable films presents a number of potential 
TABLE II - Physicochemical properties of the gelatin/chitosan 
films
FN Average thickness (mm) Tensile strength (MPa)
1 0.058 ± 0.0031 29.8 ± 2.1
2 0.060 ± 0.0075 31.2 ± 6.5
3 0.061 ± 0.0024 31.5 ± 4.9
4 0.064 ± 0.0069 33.3 ± 5.2
5 0.065 ± 0.0038 34.9 ± 3.6
6 0.067 ± 0.0052 36.5 ± 6.5
7 0.069 ± 0.0047 33.5 ± 4.1
8 0.072 ± 0.0091 32.5 ± 5.3
9 0.073 ± 0.0064 30.1 ± 3.9
10 0.075 ± 0.0082 23.7 ± 4.7
11 0.079 ± 0.0025 17.4 ± 2.8
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advantages in biomaterials. Therefore, the solubility of 
the films at gastrointestinal pH was studied. As shown 
in Table III, the solubility of the blended films in SIF 
and SCF decreased rapidly as the chitosan content 
increased. The solubility of the chitosan film was 14% 
and 18% in SIF and SCF when treated for 24 h at room 
temperature, respectively. It reveals that the blend ratio 
had a significant effect on the solubility of the film. This 
may be because gelatin is a water‑soluble polymer and 
because chitosan is insoluble in pure water at neutral pH 
but soluble in acidic solutions.
The films were easy to prepare by casting or 
spraying methods. The properties of the composite 
films were evaluated and these films are experimentally 
economical and statistically efficient (Pinotti et al., 
2007). The degradation behaviors of the chitosan/
gelatin complexes were investigated as films. In vitro 
degradation tests of the chitosan/gelatin films were 
conducted by immersing the films in the SGF, SIF and 
SCF. The effect of chitosan content on degradation 
is presented in Table III. The biodegradability of the 
composite film in SIF rapidly decreased with the 
increasing chitosan content. The biodegradability of the 
blended film in SCF also declined when the chitosan 
content increased, but the trend was not obvious when the 
blended film ratio was 1:1. This phenomenon was in line 
with studies that reported that chitosan is susceptible to 
glycosidic hydrolysis by microbial enzymes in the colon 
(Chourasia, Jain, 2003; McConnell, Murdan, Basit, 2008; 
Vargas et al., 2009).
Results of the RSR Test to Evaluate Preparations 
with Different Compositions
Because all indices were not simply positively 
correlated or negatively correlated, the RSR method was 
used to evaluate all these films. Data of RSR test was 
indicated in Table III. From Table I and Table III, we learn 
that FN5, that is the chitosan/gelatin/PEG (6:4:1, w/w/w) 
film, was relatively optimal.
Evaluation of the optimal film
FTIR
The changes in the structure of chitosan film were 
examined by FTIR spectroscopy as shown in Figure 2. 
The FTIR spectra of the gelatin, gelatin/chitosan and 
chitosan films showed a broad peak between 2800 and 
3500 cm−1, attributed to the stretching of OH bonds and 
to the hydrogen bridges in films with PEG. The gelatin/
chitosan films had wider peaks in that region, possibly due 
to strong interactions between gelatin and chitosan. This 
result agreed with those reported by Rueda, Secall, Bayer 
(1999); Mansur, Oréfice, Mansur (2004) who observed a 
broadened peak around 3400 cm−1.
DSC
Cao‘s reports indicated that the non‑covalent 
interactions were formed between the gelatin and chitosan 
molecules when the film was formed (Cao, Fu, He, 2007). 
To investigate whether each ingredient of the complex 
TABLE III - Results of the RSR test
FN
TS(MPa) QI (%) QC (%) SI (%) SC (%) DI (%) DC (%)
RSR
X1 R1 X2 R2 X3 R3 X4 R4 X5 R5 X6 R6 X7 R7
1 29.8 3 ‑ 1 ‑ 1 90 1 91 11 93 1 94 11 0.34
2 31.2 5 ‑ 1 ‑ 1 80 2 86 10 82 2 87 10 0.34
3 31.5 6 272 3 339 11 58 3 83 9 66 3 85 9 0.49
4 33.3 8 204 4 279 10 42 4 70 8 48 4 72 8 0.49
5 34.9 10 176 5 253 9 30 5 36 7 45 5 55 7 0.49
6 36.5 11 102 10 157 6 24 6 25 5 39 7 48 4 0.49
7 33.5 9 100 11 164 7 24 6 29 6 44 6 52 6 0.55
8 32.5 7 114 6 168 8 23 8 24 4 30 9 49 5 0.52
9 30.1 4 104 9 113 3 20 10 21 3 31 8 36 3 0.47
10 23.7 2 107 7 117 4 21 9 19 2 25 10 31 1 0.43
11 17.4 1 105 8 119 5 14 11 18 1 17 11 32 2 0.49 
X1–X7 are the values for the TS, QI, QC, SI, SC, DI, and DC, respectively. R1–R7 are the ranks of the TS, QI, QC, SI, SC, DI, and 
DC, respectively.
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film interacted with each other, the DSCs of the gelatin, 
chitosan, PEG, gelatin/chitosan/PEG mixture and gelatin/
chitosan films were performed. As shown in Figure 3, the 
gelatin/chitosan/PEG powder mixture had an endothermic 
transition at approximately 200 °C. However, the complex 
film did not show any endothermic or exothermic transition. 
As expected, these results suggested that interactions were 
produced among gelatin, chitosan and PEG when the film 
was formed, which was similar to the resulst reported by 
Sebti et al. (2007) and Cao, Fu, He (2007). 
SEM
Scanning electron microscopy images of the 
gelatin, chitosan and gelatin/chitosan films are shown 
in Figure 4. Figure 4 A shows that the structure of the 
gelatin film was homogeneous, convex and continuous. 
The chitosan and gelatin/chitosan films were smooth and 
had compact structures, as shown in Figures 4 B and C. 
These observations agree with reports that the surface 
of chitosan films presents as a smooth, continuous and 
compact structure (Ghaffari, 2007; Yu et al., 2011). 
This indicates that the presence of gelatin hardly caused 
structural changes in the chitosan film when the chitosan/
gelatin blend ratio was 6:4.
Biodegradation of the optimal film in rat colonic 
medium
The study of the degradation rate of the optimal film 
was conducted by immersing the film samples in rat colonic 
medium. The degradation profile of the optimal film is 
shown in Fig. 5. The biodegradability of the optimal film 
in rat colonic medium increased sharply to 65% after 24 h. 
Under the same conditions, the degradation was only 32% 
in SCF. A significant difference between the weight losses 
of the optimal film in rat colonic medium and in SCF was 
observed. Rat cecal contents contained more enzymes 
secreted by a variety of bacterial species. Chitosan is easily 
degraded by glycosidic hydrolysis by microbial enzymes 
in the colon (Finegold, 1977; Gamelin et al., 1998; Yang, 
2008). Salyers, Leedle (1983) demonstrated that more 
than one bacterial enzyme was involved in the digestion of 
polysaccharides. Thus, the rat bacterial enzymes were more 
effective in degrading chitosan film than pectinase enzyme, 
promoting the degradation of the film by bacterial enzymes. 
Attributes of core tablets
The average weight of the uncoated core tablets 
was 200 mg. The hardness of the tablets was 4.6 kg/
FIGURE 2 - FTIR spectra of gelatin (A), gelatin/chitosan (B) 
and chitosan (C) films.
FIGURE 3 - DSC curves of gelatin/chitosan/PEG mixture (A) 
gelatin/chitosan films (B), chitosan (C), gelatin (D) and PEG (E).
FIGURE 4 - SEM images of the surfaces of gelatin (A); chitosan (B) and gelatin/chitosan (C) films.
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cm2, and their friability ranged from 0.08% to 0.20% 
(w/w). The uncoated tablets were prepared using 1% 
PVPP (w/w).
In vitro drug release studies in simulated 
gastrointestinal fluids
The in vitro release studies were performed in 
medium at different pHs at 37 ºC ± 0.5 ºC. As was shown 
in Fig.6 A, the uncoated and gelatin/chitosan‑coated 
tablets showed immediate release characteristics in SGF, 
compared with the Eudragit and bilayer‑coated tablets. 
However, the Eudragit coating prevented drug release in 
SGF at pH 1.2 but allowed for rapid and complete drug 
release in SIF when the pH was raised to pH 7.4. There was 
no measurable drug release for bilayer‑coated tablets up 
to 2 h in SGF (pH 1.2). In SIF at pH 7.4, the drug release 
was negligible (<5%) up to 4 h. Thus, the bilayer coating 
prevented drug release in SGF and SIF. After dissolution, 
the bilayer-coated tablet was tested in SGF for 2h and 
SIF for 4h, and its dissolution was further detected in 
SCF. The drug release in the bilayer‑coated tablet in SCF 
increased over time, and the drug was almost completely 
released after 24 h (Fig.6 B). Therefore, the Eudragit and 
chitosan/gelatin‑coated tablets would likely resist release 
in the upper GI tract and thereby, prevent drug release at 
non‑targeted sites.
Stability studies 
Accelerated stability studies were carried out for 
a duration of 6 months as per ICH guidelines. As shown 
in Table IV, the formulation was stable according to the 
evaluation of the formulation for physical appearance, 
drug content and drug release profile.
FIGURE 5 ‑ Biodegradation of the optimal film in SCF and 
RCM.
FIGURE 6 - Dissolution profiles of uncoated tablet and gelatin/chitosan, Eudragit and bilayer-coated tablets in SGF and SIF (A), 
and bilayer-coated tablet in SCF after it was tested in SGF for 2 h and SIF for 4 h (B).
TABLE IV - Physicochemical properties of bilayer‑coated tablet during 6‑month accelerated stability studies
Time (months) Appearance Drug content (%)
Release (%)
SGF (2h) SIF (4h) SCF (24h)
1 no change 98.67±0.73 – 3.83±0.05 92.35±0.78
2 no change 98.21±0.35 – 2.98±0.07 91.88±0.54
3 no change 98.32±0.48 – 3.32±0.06 92.12±0.69
6 no change 97.72±0.69 – 3.58±0.05 91.36±0.42
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CONCLUSION
We have designed a new microbially triggered 
system based on chitosan for colonic drug delivery. The 
characteristics of the designed complex film depend on 
the chitosan/gelatin blend ratio; a 6:4 blend ratio was 
optimal. The Eudragit and chitosan/gelatin bilayer coating 
system prevented drug release in SGF and SIF. The drug 
was almost completely released in SCF after 24 h. Colon‑
targeted drug delivery was achieved by using a chitosan/
gelatin complex film and a multilayer coating system.
ACKNOWLEDGEMENTS
Our study was supported by the Wu Liande Fund for 
the Youth of Harbin Medical University (WLD‑QN1111) 
and Harbin Medical University Scientific Research 
Innovation Fund No 2016LCZX68.
REFERENCES
BERGO, P.; SOBRAL, P.J.A. Effects of plasticizer on physical 
properties of pigskin gelatin films. Food Hydrocoll., v.21, 
p.1285‑1289, 2007.
BHATTARAI, N.; GUNN, J.; ZHANG, M. Chitosan-based 
hydrogels for controlled, localized drug delivery. Adv. Drug 
Deliv. Rev., v.62, n.1, p.83‑99, 2010.
CAO, N.; FU, Y.; HE, J. Preparation and physical properties 
of soy protein isolate and gelatin composite films. Food 
Hydrocoll., v.21, p.1153‑1162, 2007.
C E L A S C O ,  G . ;  M O R O ,  L . ;  B O Z Z E L L A ,  R . ; 
MANGANANGANO, K.; QUATTROCCHI, C.; AIELLO, 
C.; DONIA, M.; FAGONE, P.; DI MARCO, R. Efficacy 
of intracolonic administration of low‑molecular‑weight 
heparin CB‑01‑05, compared to other low‑molecular‑weight 
heparins and unfractionated heparin, in experimentally 
induced colitis in rat. Dig. Dis. Sci., v.53, n.12, p.3170‑
3175, 2008.
CHOURASIA, M.K.; JAIN, S.K. Pharmaceutical approaches 
to colon targeted drug delivery systems. J. Pharm. Pharm. 
Sci., v.6, n.1, p.33‑66, 2003.
CHOURASIA, M.K.; JAIN, S.K. Polysaccharides for colon 
targeted drug delivery. Drug Deliv., v.11, n.2, p.129‑148, 
2004.
CUI, F.D.; JIE, J.; LI, W.; HONGZE, P.; WENHUI, L.; 
DONGMEI, C. Preparation and in vitro evaluation of pH, 
time‑based and enzyme‑degradable pellets for colonic drug 
delivery. Drug Dev. Ind. Pharm., v.33, n.9, p.999‑1007, 
2007. 
CUMMINGS, J.H.; MACFARLANE, G.T. The control and 
consequences of bacterial fermentation in the human colon. 
J. Appl. Bacteriol., v.70, n.6, p.443‑459, 1991.
DEV, R.K.; BALI, V.; PATHAK, K. Novel microbially triggered 
colon specific delivery system of 5-Fluorouracil: Statistical 
optimization, in vitro, in vivo, cytotoxic and stability 
assessment. Int. J. Pharm., v.411, n.1‑2, p.142‑151, 2011. 
DHANESHWAR, S.S.; GAIROLA, N.; KANDPAL, M.; 
VADNERKAR, G.; BHATT, L. Colon‑specific, mutual 
azo prodrug of 5‑aminosalicylic acid with L‑tryptophan: 
synthesis, kinetic studies and evaluation of its mitigating 
effect in trinitrobenzenesulfonic acid‑induced colitis in 
rats. Bioorg. Med. Chem., v.15, n.14, p.4903‑4909, 2007.
DI  P IERRO,  P. ;  CHICO,  B . ;  VILLALON GA,  R . ; 
MARINIELLO, L.; DAMIAO, A.E.; MASI, P.; PORTA, 
R. Chitosan‑whey protein edible films produced in the 
absence or presence of transglutaminase: analysis of their 
mechanical and barrier properties. Biomacromolecules. v.7, 
n.3, p.744‑749, 2006. 
ENGLYST, H.N.; CUMMINGS, J.H. Digestion of the 
polysaccharides of some cereal foods in the human small 
intestine. Am. J. Clin. Nutr., v.42, n.5, p.778‑787, 1985. 
FAN, L.F.; HE, W.; CHANG, Y.Z.; XIANG, B.; DU, Q.; WANG, 
F.; QIN, M.; CAO, D.Y. Studies of chitosan/Kollicoat SR 
30D film-coated tablets for colonic drug delivery. Int. J. 
Pharm., v.375, n.1‑2, p.8‑15, 2009. 
FINEGOLD, S.M.; SUTTER, V.L.; SUGIHARA, P.T.; ELDER, 
H.A.; LEHMANN, S.M.; PHILLIPS, R.L. Fecal microbial 
flora in Seventh Day Adventist populations and control 
subjects. Am. J. Clin. Nutr., v.30, n.11, p.1781‑1792, 1977. 
Y. Ren, L. Jiang, S. Yang, S. Gao, H. Yu, J. Hu, D. Hu, W. Mao, H. Peng, Y. Zhou
Braz. J. Pharm. Sci. 2017;53(1):e15009Page 10 / 11
GAMELIN, E.; BOISDRON-CELLE, M.; DELVA, R.; 
REGIMBEAU, C.; CAILLEUX, P.E.; ALLEAUME, C.; 
MAILLET, M.L.; GOUDIER, M.J.; SIRE, M.; PERSON-
JOLY, M.C.; MAIGRE, M.; MAILLART, P.; FETY, 
R.; BURTIN, P.; LORTHOLARY, A.; DUMESNIL, Y.; 
PICON, L.; GESLIN, J.; GESTA, P.; DANQUECHIN-
DORVAL, E.; LARRA, F.; Robert, J. Long‑term weekly 
treatment of colorectal metastatic cancer with fluorouracil 
and leucovorin: results of a multicentric prospective trial 
of fluorouracil dosage optimization by pharmacokinetic 
monitoring in 152 patients. J. Clin. Oncol., v.16, n.4, 
p.1470‑1478, 1998.
GHAFFARI, A.; NAVAEE, K.; OSKOUI, M.; BAYATI, K.; 
RAFIEE‑TEHRANI, M. Preparation and characterization 
of free mixed-film of pectin/chitosan/Eudragit RS intended 
for sigmoidal drug delivery. Eur. J. Pharm. Biopharm., v.67, 
n.1, p.175‑186, 2007. 
GUARNER, F.; MALAGELADA, J.R. Gut flora in health and 
disease. Lancet, v.361, n.9356, p.512‑519, 2003. 
GUPTA, V.K.; BECKERT, T.E.; PRICE, J.C. A novel pH‑ and 
time‑based multi‑unit potential colonic drug delivery 
system. I. Development. Int. J. Pharm., v.213, p.83‑91, 
n,1‑2, 2001.
JAIN, S.K.; JAIN, A. Target-specific drug release to the colon. 
Expert. Opin. Drug Deliv., v.5, n.5, p.483‑498, 2008. 
JOSE, S.; PREMA, M.T.; CHACKO, A.J.; THOMAS, A.C.; 
SOUTO, E. Colon specific chitosan microspheres for 
chronotherapy of chronic stable angina. Colloids. Surf. 
B. Biointerfaces., v.83, n.2, p.277‑283, 2011. (There is 
no citation linked with this reference in the text. Verify, 
please!!)
LIU, H.; YANG, X.; NIE, S.F.; WEI, L.L.; ZHOU, L.L.; LIU, H.; 
TANG, R.; PAN, W.S. Chitosan‑based controlled porosity 
osmotic pump for colon-specific delivery system: screening 
of formulation variables and in vitro investigation. Int. J. 
Pharm., v.332, n.1/2, p.115‑124, 2007. 
LORENZO‑LAMOSA, M.L.; REMUNAN‑LOPEZ, C.; VILA‑
JATO, J.L.; ALONSO, M.J. Design of microencapsulated 
chitosan microspheres for colonic drug delivery. J. Control. 
Release, v.52, n.1/2, p.109‑118, 1998.
 
LUO, J.; ZHONG, Y.; CAO, J.; CUI, H. Efficacy of oral colon-
specific delivery capsule of low-molecular-weight heparin 
on ulcerative colitis. Biomed. Pharmacother., v.65, n.2, 
p.111‑117, 2011. 
MANO, J.F.; SILVA, G.A.; AZEVEDO, H.S.; MALAFAYA, 
P.B.; SOUSA, R.A.; SILVA, S.S.; BOESEL, L.F.; 
OLIVEIRA, J.M.; SANTOS, T.C.; MARQUES, A.P.; 
NEVES, N.M.; REIS, R.L. Natural origin biodegradable 
systems in tissue engineering and regenerative medicine: 
present status and some moving trends. J. R. Soc. Interface, 
v.4, n.17, p.999‑1030, 2007. 
MANSUR, H.S.; ORÉFICE, R.L.; MANSUR, A.A.P. 
Characterization of poly(vinyl alcohol)/poly(ethylene 
glycol) hydrogels and PVA‑derived hybrids by small‑angle 
X‑ray scattering and FTIR spectroscopy. Polymer, v.45, 
p.7193‑7202, 2004.
MCCONNELL, E.L.; MURDAN, S.; BASIT, A.W. An 
investigation into the digestion of chitosan (noncrosslinked 
and crosslinked) by human colonic bacteria. J. Pharm. Sci., 
v.97, n.9, p.3820‑3829, 2008. 
MUZZARELLI, R.A. Biomedical exploitation of chitin 
and chitosan via mechano‑chemical disassembly, 
electrospinning, dissolution in imidazolium ionic liquids, 
and supercritical drying. Mar. Drugs, v.9, n.9, p.1510‑1533, 
2011. 
NATH, B.; NATH, L.K. Studies on stercuia gum formulations 
in the form of osmotic core tablet for colon-specific drug 
delivery of azathioprine. PDA J. Pharm. Sci. Technol., v.67, 
n.2, p.172‑184, 2013.
NAGENDRA, R.; ROOPA, S.P.; GURINDER, S. Design and 
optimization of novel in situ gel of mercaptopurine for 
sustained drug delivery. Braz. J. Pharm. Sci., v.50, n.2, 
p.107‑119, 2014. 
PARK, J.H.; SARAVANAKUMAR, G.; KIM, K.; KWON, I.C. 
Targeted delivery of low molecular drugs using chitosan 
and its derivatives. Adv. Drug. Deliv. Rev., v.62, n.1, p.28‑
41, 2010. 
PINOTTI, A.; GARCÍA, M.A.; MARTINO, M.N.; ZARITZKY, 
N.E. Study on microstructure and physical properties of 
composite films based on chitosan and methylcellulose. 
Food Hydrocoll., v.21, n.1, p.66‑72, 2007. 
Design and preparation of a novel colon-targeted tablet of hydrocortisone
Braz. J. Pharm. Sci. 2017;53(1):e15009 Page 11 / 11
PRODPRAN, T.; BENJAKUL, S.; ARTHARN, A. Properties 
and microstructure of protein-based film from round scad 
(Decapterus maruadsi) muscle as affected by palm oil and 
chitosan incorporation. Int. J. Biol. Macromol., v.41, n.5, 
p.605‑610, 2007. 
RUBINSTEIN, A. Approaches and opportunities in colon‑
specific drug delivery. Crit. Rev. Ther. Drug Carrier Syst., 
v.12, n.2‑3, p.101‑149, 1995.
RUEDA, D.R.; SECALL, T.; BAYER, R.K. Differences in 
the interaction of water with starch and chitosan films as 
revealed by infrared spectroscopy and differential scanning 
calorimetry. Carbohyd. Polym., v.40, n.1, p.49‑56, 1999. 
SALYERS, A.A.; LEEDLE, J.A. Carbohydrate metabolism 
in the human colon. In: HENTGES, D.J. (ed.). Human 
intestinal microflora in health and disease. New York: 
Academic Press, 1983. p.129‑146.
SEBTI, I.; CHOLLET, E.; DEGRAEVE, P.; NOEL, C.; 
PEYROL, E. Water sensitivity, antimicrobial, and 
physicochemical analyses of edible films based on HPMC 
and/or chitosan. J. Agric. Food Chem., v.55, n.3, p.693‑
699, 2007. 
SINGLA, A.K.; CHAWLA, M. Chitosan: some pharmaceutical 
and biological aspects‑an update. J. Pharm. Pharmacol., 
v.53, n.8, p.1047‑1067, 2001.
TOZAKI, H.; ODORIBA, T.; OKADA, N.; FUJITA, T.; 
TERABE, A.; SUZUKI, T.; OKABE, S.; MURANISHI, S.; 
YAMAMOTO, A. Chitosan capsules for colon-specific drug 
delivery: enhanced localization of 5‑aminosalicylic acid in 
the large intestine accelerates healing of TNBS‑induced 
colitis in rats. J. Control. Release, v.82, n.1, p.51‑61, 2002. 
VAGHANI, S.S.; PATEL, M.M.; SATISH, C.S. Synthesis 
and characterization of pH‑sensitive hydrogel composed 
of carboxymethyl chitosan for colon targeted delivery of 
ornidazole. Carbohydr. Res., v.347, n.1, p.76‑82, 2012. 
VARGAS, M.; ALBORS, A.; CHIRALT, A.; GONZÁLEZ-
MARTÍNEZ, C. Characterization of chitosan‑oleic acid 
composite films. Food Hydrocoll.,, v.23, n.2, p.536‑547, 
2009.
YANG, L. Biorelevant dissolution testing of colon‑specific 
delivery systems activated by colonic microflora. J. Control. 
Release, v.125, n.2, p.77‑86, 2008. 
YIN, H.Q.; LEE, E.S.; KIM, D.; LEE, K.H.; OH, K.T.; BAE, 
Y.H. Physicochemical characteristics of pH‑sensitive 
poly(L‑Histidine)‑b‑poly (ethylene glycol)/poly(L‑
Lactide)‑b‑poly(ethylene glycol) mixed micelles. J. 
Control. Release, v.126, n.2, p.130‑138, 2008. 
YU, Q.; SONG, Y.; SHI, X.; XU, C.; BIN, Y. Preparation and 
properties of chitosan derivative/poly(vinyl alcohol) blend 
film crosslinked with glutaraldehyde. Carbohyd. Polym., 
v.84, n.1, p.465‑470, 2011. 
ZAMBITO, Y.; DI COLO, G. Preparation and in vitro evaluation 
of chitosan matrices for colonic controlled drug delivery. J. 
Pharm. Pharm. Sci., v.6, n.2, p.274‑281, 2003. 
ZHANG, H.; ALSARRA, I.A.; NEAU, S.H. An in vitro 
evaluation of a chitosan‑containing multiparticulate system 
for macromolecule delivery to the colon. Int. J. Pharm., 
v.239, n.1/2, p.197‑205, 2002.
Received for publication on 15th January 2015
Accepted for publication on 24th October 2016
